<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05008367</url>
  </required_header>
  <id_info>
    <org_study_id>SM1-KAKG-2021</org_study_id>
    <nct_id>NCT05008367</nct_id>
  </id_info>
  <brief_title>Effect of Dexamethasone as Analgesic Treatment After Total Knee Arthroplasty</brief_title>
  <official_title>Effect of Dexamethasone as Analgesic Treatment After Total Knee Arthroplasty: Subgroup Analyses of The DEX-2-TKA Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Naestved Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Copenhagen Trial Unit, Center for Clinical Intervention Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Naestved Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Effect of Dexamethasone as Analgesic Treatment After Total Knee Arthroplasty: Subgroup&#xD;
      Analyses of The DEX-2-TKA Randomized Clinical Trial This explorative post-hoc analysis is a&#xD;
      substudy of the DEX-2-TKA-trial (NCT03506789) investigating diffefferent subgroups of the&#xD;
      patients included in the main trial.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Effect of Dexamethasone as Analgesic Treatment After Total Knee Arthroplasty: Subgroup&#xD;
      Analyses of The DEX-2-TKA Randomized Clinical Trial This explorative post-hoc analysis is a&#xD;
      substudy of the DEX-2-TKA-trial (NCT03506789) investigating diffefferent subgroups of the&#xD;
      patients included in the main trial.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 14, 2018</start_date>
  <completion_date type="Actual">June 7, 2020</completion_date>
  <primary_completion_date type="Actual">March 11, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative usage of morphine 0-48 hours postoperatively</measure>
    <time_frame>Time Frame: 0-48 hours postoperatively</time_frame>
    <description>Morphine administered both as patient-controlled analgesia (PCA) i.v. morphine 0-24 hours and oral morphine on demand 24-48 hours, and any other supplemental morphine administered postoperatively. Consumption in mg</description>
  </primary_outcome>
  <other_outcome>
    <measure>Subgroup analysis on heterogeneity in intervention effect of age</measure>
    <time_frame>Time Frame: 0-48 hours postoperatively</time_frame>
    <description>Age (years): &gt; 65 vs. ≤ 65</description>
  </other_outcome>
  <other_outcome>
    <measure>Subgroup analysis on heterogeneity in intervention effect of sex</measure>
    <time_frame>Time Frame: 0-48 hours postoperatively</time_frame>
    <description>Sex: male vs. female</description>
  </other_outcome>
  <other_outcome>
    <measure>Subgroup analysis on heterogeneity in intervention effect of ASA group</measure>
    <time_frame>Time Frame: 0-48 hours postoperatively</time_frame>
    <description>ASA group classification: I+II vs. III</description>
  </other_outcome>
  <other_outcome>
    <measure>Subgroup analysis on heterogeneity in intervention effect of preoperative pain at rest</measure>
    <time_frame>Time Frame: 0-48 hours postoperatively</time_frame>
    <description>VAS (mm): &gt; 30 vs. ≤ 30</description>
  </other_outcome>
  <other_outcome>
    <measure>Subgroup analysis on heterogeneity in intervention effect of preoperative pain when active</measure>
    <time_frame>Time Frame: 0-48 hours postoperatively</time_frame>
    <description>VAS (mm): &gt; 30 vs. ≤ 30</description>
  </other_outcome>
  <other_outcome>
    <measure>Subgroup analysis on heterogeneity in intervention effect of type of anesthesia</measure>
    <time_frame>Time Frame: 0-48 hours postoperatively</time_frame>
    <description>Type of anesthesia: spinal vs. general Anesthesia+Converted to general anesthesia</description>
  </other_outcome>
  <other_outcome>
    <measure>Subgroup analysis on heterogeneity in intervention effect of prior daily use (last month) of analgesic medication</measure>
    <time_frame>Time Frame: 0-48 hours postoperatively</time_frame>
    <description>Prior daily use of paracetamol or NSAID: either parecetamol or NSAID vs. neither parecetamol or NSAID</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">485</enrollment>
  <condition>Postoperative Pain</condition>
  <arm_group>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>24 mg dexamethasone i.v. perioperatively and 24 mg dexamethasone i.v. on the first postoperative day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>24 mg dexamethasone i.v. perioperatively and placebo (isotonic saline) i.v. on the first postoperative day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (isotonic saline) i.v. perioperatively and placebo (isotonic saline) i.v. on the first postoperative day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>24 mg intravenous Dexamethasone (6 ml)</description>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_label>Treatment B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isotonic saline</intervention_name>
    <description>6 ml of isotonic saline</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Treatment B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participation in the DEX-2-TKA-trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Gildhøj Privathospital</name>
      <address>
        <city>Brøndbyvester</city>
        <zip>2605</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bispebjerg Hospital</name>
      <address>
        <city>Copenhagen</city>
        <zip>2400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sjællands Universitetshospital, Køge</name>
      <address>
        <city>Køge</city>
        <zip>4600</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Næstsved Sygehus</name>
      <address>
        <city>Næstved</city>
        <zip>4700</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odense Universitetshospital</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 13, 2021</study_first_submitted>
  <study_first_submitted_qc>August 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 17, 2021</study_first_posted>
  <last_update_submitted>September 6, 2021</last_update_submitted>
  <last_update_submitted_qc>September 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 23, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/67/NCT05008367/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

